on ABIONYX (EPA:ABNX)
ABIONYX Pharma Achieves Unanimous Approval at Combined General Meeting
ABIONYX Pharma, a biotech firm specializing in innovative therapies, announced the unanimous approval of all resolutions at its Combined General Meeting. This includes the renewal of key mandates and the continuation of the share buyback program and liquidity contract.
The resolutions included the renewal of M. Christian Chavy as Director and BPI FRANCE Participations, represented by M. Olivier Martinez, as censor for a three-year term. All votes were in favor, reflecting strong shareholder support.
ABIONYX Pharma expressed gratitude to all shareholders who participated, whether in person, represented, or by postal vote. Detailed meeting minutes and voting results are available on the company's website.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIONYX news